These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor. Slevin JT; Gerhardt GA; Smith CD; Gash DM; Kryscio R; Young B J Neurosurg; 2005 Feb; 102(2):216-22. PubMed ID: 15739547 [TBL] [Abstract][Full Text] [Related]
23. GDNF in Parkinson's disease: the perils of post-hoc power. Matcham J; McDermott MP; Lang AE J Neurosci Methods; 2007 Jul; 163(2):193-6. PubMed ID: 17540454 [TBL] [Abstract][Full Text] [Related]
24. New and emerging treatments for Parkinson disease. Fung VS Med J Aust; 2015 Apr; 202(6):283-4. PubMed ID: 25832138 [No Abstract] [Full Text] [Related]
25. Parkinson's disease. Clarke C; Moore AP Clin Evid; 2002 Jun; (7):1208-20. PubMed ID: 12230738 [No Abstract] [Full Text] [Related]
26. Encapsulated cell biodelivery of GDNF: a novel clinical strategy for neuroprotection and neuroregeneration in Parkinson's disease? Lindvall O; Wahlberg LU Exp Neurol; 2008 Jan; 209(1):82-8. PubMed ID: 17963752 [TBL] [Abstract][Full Text] [Related]
27. Disease process and drug treatments in Parkinson's disease. Leenders KL Eur Neuropsychopharmacol; 2002 Dec; 12(6):575-80. PubMed ID: 12468020 [No Abstract] [Full Text] [Related]
28. Parkinson disease: Can a new trial end controversy over when to use levodopa? Rascol O Nat Rev Neurol; 2014 Sep; 10(9):488-9. PubMed ID: 25134709 [TBL] [Abstract][Full Text] [Related]
29. [Parkinson disease. Value of COMT inhibitors is verified]. MMW Fortschr Med; 2001 May; 143(18):51. PubMed ID: 11387711 [No Abstract] [Full Text] [Related]
30. Assessment of GDNF in primate models of Parkinson's disease: comparison with human studies. Eslamboli A Rev Neurosci; 2005; 16(4):303-10. PubMed ID: 16519007 [TBL] [Abstract][Full Text] [Related]
32. The comparative effects of medical therapies for Parkinson's disease. Horn S; Stern MB Neurology; 2004 Oct; 63(7 Suppl 2):S7-12. PubMed ID: 15477585 [No Abstract] [Full Text] [Related]
33. Application of a blood-brain-barrier-penetrating form of GDNF in a mouse model for Parkinson's disease. Dietz GP; Valbuena PC; Dietz B; Meuer K; Müeller P; Weishaupt JH; Bähr M Brain Res; 2006 Apr; 1082(1):61-6. PubMed ID: 16703672 [TBL] [Abstract][Full Text] [Related]
34. Early-stage Parkinson's disease: to treat or not to treat. Jankovic J; Shoulson I; Weiner WJ Neurology; 1994 Mar; 44(3 Suppl 1):S4-7. PubMed ID: 8121578 [No Abstract] [Full Text] [Related]
35. MRI volumetric and intensity analysis of the cerebellum in Parkinson's disease patients infused with glial-derived neurotrophic factor (GDNF). Chebrolu H; Slevin JT; Gash DA; Gerhardt GA; Young B; Given CA; Smith CD Exp Neurol; 2006 Apr; 198(2):450-6. PubMed ID: 16455079 [TBL] [Abstract][Full Text] [Related]
36. Underrepresentation of women in Parkinson's disease trials. Tosserams A; Araújo R; Pringsheim T; Post B; Darweesh SKL; IntHout J; Bloem BR Mov Disord; 2018 Nov; 33(11):1825-1826. PubMed ID: 30311268 [No Abstract] [Full Text] [Related]